Fruzaqla Drug Class
Fruzaqla (fruquintinib) is a kinase inhibitor, specifically an orally administered selective tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR) 1,2, and 3 1.
Mechanism of Action
Fruquintinib functions as a highly selective small molecule kinase inhibitor with the following characteristics 1:
- Primary targets: VEGFR-1, VEGFR-2, and VEGFR-3
- IC50 values: 33 nM, 35 nM, and 0.5 nM respectively
- Mechanism: Inhibits VEGF-mediated endothelial cell proliferation and tubular formation in vitro
- Effect: Blocks VEGF-induced VEGFR-2 phosphorylation, leading to tumor growth inhibition
Clinical Classification Context
Within the broader therapeutic landscape, fruquintinib belongs to the anti-angiogenic targeted therapy class used in metastatic colorectal cancer 2. The NCCN guidelines specifically categorize it alongside other VEGFR inhibitors like regorafenib as treatment options for refractory mCRC that has progressed through all standard therapies 2.
Key Distinguishing Features
- Selectivity: Unlike multi-kinase inhibitors, fruquintinib is highly selective for all three VEGF receptors 3, 4
- Route: Oral administration (capsules containing 1 mg or 5 mg fruquintinib) 1
- Dosing schedule: 5 mg once daily for 21 days of each 28-day cycle 1
Pharmacologic Properties
The drug demonstrates typical kinase inhibitor characteristics 1: